目的 探讨正天胶囊联合盐酸洛美利嗪胶囊治疗偏头痛的临床疗效。方法 选择2020年4月—2021年4月在驻马店市中心医院治疗的102例偏头痛患者，根据药物使用的差别分为对照组和治疗组，每组各51例。对照组口服盐酸洛美利嗪胶囊，5 mg/次，2次/d；治疗组在对照组基础上口服正天胶囊，0.9 g/次，3次/d。两组均用药2周。观察两组患者临床疗效，比较治疗前后两组患者脑血流速度、临床症状，PSQI、MSQ和VAS评分，及血清血管性血友病因子（vWF）、垂体腺苷酸环化酶激活肽（PACAP）、5-羟色胺（5-HT）、β-内啡肽（β-EP）和降钙素基因相关肽（CGRP）水平。结果 经治疗，对照组和治疗组的总有效率分别为84.31%和98.04%（P<0.05）。经治疗，两组大脑后动脉（PCA）、大脑前动脉（ACA）、基底动脉（BA）、大脑中动脉（MCA）、椎动脉（VA）的血流速度均降低（P<0.05），且治疗组更显著（P<0.05）。经治疗，两组头痛发作次数和头痛持续时间上均改善（P<0.05），且治疗组更明显（P<0.05）。经治疗，两组患者PSQI评分和MSQ评分明显升高，而VAS评分明显降低（P<0.05），且治疗组评分明显好于对照组（P<0.05）。经治疗，两组患者血清CGRP、vWF、β-EP、PACAP水平明显降低，而5-HT水平明显升高（P<0.05），且治疗组血清学指标水平明显好于对照组（P<0.05）。结论 正天胶囊联合盐酸洛美利嗪胶囊治疗偏头痛能够有效改善患者临床症状，促进脑血流情况改善，改善机体细胞因子水平，提高患者睡眠及生活质量。

Objective To investigate the clinical effect of Zhengtian Capsules combined with lomerizine in treatment of migraine. Methods Patients (102 cases) with migraine in Zhumadian Central Hospital from April 2020 to April 2021 were divided into control and treatment groups according to different treatments, and each group had 51 cases. Patients in the control group were po administered with Lomerizine Hydrochloride Capsules, 5 mg/time, twice daily. Patients in the treatment group were po administered with Zhengtian Capsules, 0.9 g/time, three times daily. Patients in two groups were treated for 2 weeks. After treatment, the clinical evaluation was evaluated, the cerebral blood flow velocity, the clinical symptoms, the scores of PSQI, MSQ, and VAS, and the levels of serum CGRP, vWF, β-EP, PACAP, and 5-HT in two groups before and after treatment were compared. Results After treatment, the effective rates of the control group and the treatment group were 84.31% and 98.04%, respectively (P<0.05). After treatment, the blood flow velocities of PCA, ACA, BA, MCA, and VA were significantly decreased in two groups (P<0.05), and which the treatment group decreased more significantly (P<0.05). After treatment, the frequency of headache attacks and the duration of headache were improved in two groups (P<0.05), and which in the treatment group was the most improved (P<0.05). After treatment, the PSQI score and MSQ score in two groups were significantly increased, while the VAS score was significantly decreased (P<0.05), and these scores in the treatment group was significantly better than that in the control group (P<0.05). After treatment, the levels of serum CGRP, vWF, β-EP, and PACAP in two groups significantly decreased, while the level of 5-HT was significantly increased (P<0.05), and these serum indexes level in the treatment group was significantly better than that in the control group (P<0.05). Conclusion Zhengtian Capsules combined with lomerizine in treatment of migraine can effectively improve the clinical symptoms, promote the improvement of cerebral blood flow, improve the level of cytokines, and improve the sleep and quality of life.

R971

河南省科技研发专项项目（172102310685）